oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2024-23-5-126-132oncotomsk-3276Research ArticleОБЗОРЫREVIEWSПротоковый рак поджелудочной железы и изолированные метастазы в печени: есть ли место для хирургического лечения?Pancreatic ductual carcinoma with isolated liver metastases: is it worth performing surgical resection?https://orcid.org/0000-0002-6603-1390ЕгоровВ. И.EgorovV. I.

Егоров Василий Иванович, кандидат медицинских наук, ассистент кафедры онкологии, лучевой диагностики и лучевой терапии, 420012, г. Казань, ул. Бутлерова, 49;

420029, г. Казань, Сибирский тракт, 29

Vasily I. Egorov, MD, PhD, Assistant, Department of Oncology, Radiation Therapy and Diagnostic Imaging, 49, Butlerov St., Kazan, 420012;

Oncologist, Department of Oncology, 29, Sibirsky trakt, Kazan, 420029

drvasiliy21@gmail.comhttps://orcid.org/0000-0002-2811-0549КотельниковА. Г.KotelnikovA. G.

Котельников Алексей Геннадьевич, доктор медицинских наук, профессор, ведущий научный сотрудник отделения абдоминальной онкологии № 2 (опухолей  гепатопанкреатобилиарной зоны), 

115522, г. Москва, Каширское шоссе, 23

Alexey G. Kotelnikov, MD, DSc, Professor, Leading Researcher, Department of Abdominal Oncology No. 2,

23, Kashirskoye shosse, Moscow, 115522

https://orcid.org/0000-0003-3953-0036КантиеваД. М.KantievaD. M.

Кантиева Даяна Магомедовна, онколог отделения лекарственных методов лечения (химиотерапевтическое) № 2, 

115522, г. Москва, Каширское шоссе, 23

Dayana M. Kantieva, MD, Oncologist, 2-nd Chemotherapy Department, 

23, Kashirskoye shosse, Moscow, 115522

https://orcid.org/0000-0003-2624-9341БазинИ. С.BazinI. S.

Базин Игорь Сергеевич, доктор медицинских наук, ведущий научный сотрудник отделения лекарственных методов лечения (химиотерапевтическое) № 2, 

115522, г. Москва, Каширское шоссе, 23

Igor S. Bazin, MD, DSc, Leading Researcher, 2-nd Chemotherapy Department,

23, Kashirskoye shosse, Moscow, 115522

ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России; ГАУЗ «Республиканский клинический онкологический диспансер» Минздрава Республики ТатарстанРоссияKazan State Medical University of the Ministry of Health of Russia; Tatarstan Regional Clinical Cancer Center of the Ministry of Health of the Republic of TatarstanRussian FederationФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава РоссииРоссияN.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of RussiaRussian Federation202414112024235126132Copyright © Егоров В.И., Котельников А.Г., Кантиева Д.М., Базин И.С., 20242024Егоров В.И., Котельников А.Г., Кантиева Д.М., Базин И.С.Egorov V.I., Kotelnikov A.G., Kantieva D.M., Bazin I.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/3276Актуальность

Актуальность. Протоковый рак поджелудочной железы – одно из самых агрессивных злокачественных новообразований с высокой частотой распространенных стадий в момент диагностики и неудовлетворительными отдаленными результатами лечения. Считается, что протоковый рак поджелудочной железы при наличии выявленных отдаленных метастазов на этапе интраоперационной ревизии или до операции является противопоказанием к хирургическому лечению. В настоящее время возобновился интерес к хирургическому лечению у пациентов с олигометастазами рака поджелудочной железы.

Материал и методы

Материал и методы. Поиск источников производился в системах PubMed, Elibrary за период с января 1995 г. по январь 2024 г. Из 1 321 найденного источника для написания обзора использованы 37. Включены данные как ретроспективных, так и проспективных клинических исследований, посвященных результатам комбинированного лечения рака поджелудочной железы с изолированными метастазами в печени.

Результаты

Результаты. На данный момент не определена тактика лечения пациентов с олигометастатическим раком поджелудочной железы, нет четких критериев отбора больных, кому показано хирургическое лечение. Существующие критерии отбора на операцию при метастатическом раке поджелудочной железы далеко не идеальны, крайне разнородны и, как правило, основаны только на определенных клинико-инструментальных данных. Отправной точкой для разработки критериев отбора для хирургического лечения больных с метастазами рака поджелудочной железы является единое понимание, что такое «олигометастатический рак поджелудочной железы».

Pancreatic ductal cancer is one of the most aggressive malignancy with a high incidence of advanced stages at the time of diagnosis and unsatisfactory long-term treatment results. It is believed that pancreatic ductal cancer in the presence of distant metastases identified at the stage of intraoperative revision or before surgery is a contraindication to surgical treatment. There is currently renewed interest in surgical treatment of patients with oligometastatic pancreatic cancer.

Material and Methods

Material and Methods. The search for sources was carried out in the PubMed and Elibrary systems from January 1995 to January 2024. Of the 1321 sources found, 37 were used to write the review. Data from both retrospective and prospective clinical studies that focused on the results of combined modality treatment of pancreatic cancer with isolated liver metastases were included.

Results

Results. To date, a standard treatment strategy for patients with oligometastatic pancreatic cancer has not yet been established; there are no definitive criteria for selecting patients who may benefit from surgical treatment. The current selection criteria for surgery for metastatic pancreatic cancer are far from ideal, extremely heterogeneous and, as a rule, are based only on certain clinical and instrumental data. The starting point for developing selection criteria for surgical treatment of patients with metastatic pancreatic cancer is a common understanding of what “oligometastatic pancreatic cancer” is.

рак поджелудочной железыолигометастатический ракпанкреатодуоденальная резекцияобщая выживаемостьрезекция поджелудочной железыpancreatic canceroligometastatic cancerpancreatoduodenalectomyoverall survivalpancreatic resectionReferencesHe J., Ahuja N., Makary M.A., Cameron J.L., Eckhauser F.E., Choti M.A., Hruban R.H., Pawlik T.M., Wolfgang C.L. 2564 resected periam pullary adenocarcinomas at a single institution: trends over three decades. HPB (Oxford). 2014; 16(1): 83–90. doi: 10.1111/hpb.12078.He J., Ahuja N., Makary M.A., Cameron J.L., Eckhauser F.E., Choti M.A., Hruban R.H., Pawlik T.M., Wolfgang C.L. 2564 resected periam pullary adenocarcinomas at a single institution: trends over three decades. HPB (Oxford). 2014; 16(1): 83–90. doi: 10.1111/hpb.12078.Louvet C., Philip P.A. Accomplishments in 2007 in the treatment of metastatic pancreatic cancer. Gastrointest Cancer Res. 2008; 2(3s): 37–41.Louvet C., Philip P.A. Accomplishments in 2007 in the treatment of metastatic pancreatic cancer. Gastrointest Cancer Res. 2008; 2(3s): 37–41.Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1): 7–30. doi: 10.3322/caac.21590.Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1): 7–30. doi: 10.3322/caac.21590.Mayo S.C., de Jong M.C., Pulitano C., Clary B.M., Reddy S.K., Gamblin T.C., Celinksi S.A., Kooby D.A., Staley C.A., Stokes J.B., Chu C.K., Ferrero A., Schulick R.D., Choti M.A., Mentha G., Strub J., Bauer T.W., Adams R.B., Aldrighetti L., Capussotti L., Pawlik T.M. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010; 17(12): 3129–36. doi: 10.1245/s10434-010-1154-5.Mayo S.C., de Jong M.C., Pulitano C., Clary B.M., Reddy S.K., Gamblin T.C., Celinksi S.A., Kooby D.A., Staley C.A., Stokes J.B., Chu C.K., Ferrero A., Schulick R.D., Choti M.A., Mentha G., Strub J., Bauer T.W., Adams R.B., Aldrighetti L., Capussotti L., Pawlik T.M. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010; 17(12): 3129–36. doi: 10.1245/s10434-010-1154-5.Ejaz A., Reames B.N., Maithel S., Poultsides G.A., Bauer T.W., Fields R.C., Weiss M.J., Marques H.P., Aldrighetti L., Pawlik T.M. Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis: a multi-institutional analysis. HPB (Oxford). 2018; 20(3): 277–84. doi: 10.1016/j.hpb.2017.08.039.Ejaz A., Reames B.N., Maithel S., Poultsides G.A., Bauer T.W., Fields R.C., Weiss M.J., Marques H.P., Aldrighetti L., Pawlik T.M. Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis: a multi-institutional analysis. HPB (Oxford). 2018; 20(3): 277–84. doi: 10.1016/j.hpb.2017.08.039.Conroy T., Desseigne F., Ychou M., Bouché O., Guimbaud R., Bécouarn Y., Adenis A., Raoul J.L., Gourgou-Bourgade S., de la Fouchardière C., Bennouna J., Bachet J.B., KhemissaAkouz F., Péré-Vergé D., Delbaldo C., Assenat E., Chauffert B., Michel P., Montoto-Grillot C., Ducreux M.; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19): 1817–25. doi: 10.1056/NEJMoa1011923.Conroy T., Desseigne F., Ychou M., Bouché O., Guimbaud R., Bécouarn Y., Adenis A., Raoul J.L., Gourgou-Bourgade S., de la Fouchardière C., Bennouna J., Bachet J.B., KhemissaAkouz F., Péré-Vergé D., Delbaldo C., Assenat E., Chauffert B., Michel P., Montoto-Grillot C., Ducreux M.; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19): 1817–25. doi: 10.1056/NEJMoa1011923.Von Hoff D.D., Ervin T., Arena F.P., Chiorean E.G., Infante J., Moore M., Seay T., Tjulandin S.A., Ma W.W., Saleh M.N., Harris M., Reni M., Dowden S., Laheru D., Bahary N., Ramanathan R.K., Tabernero J., Hidalgo M., Goldstein D., van Cutsem E., Wei X., Iglesias J., Renschler M.F. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18): 1691–703. doi: 10.1056/NEJMoa1304369.Von Hoff D.D., Ervin T., Arena F.P., Chiorean E.G., Infante J., Moore M., Seay T., Tjulandin S.A., Ma W.W., Saleh M.N., Harris M., Reni M., Dowden S., Laheru D., Bahary N., Ramanathan R.K., Tabernero J., Hidalgo M., Goldstein D., van Cutsem E., Wei X., Iglesias J., Renschler M.F. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18): 1691–703. doi: 10.1056/NEJMoa1304369.Crippa S., Bittoni A., Sebastiani E., Partelli S., Zanon S., Lanese A., Andrikou K., Muffatti F., Balzano G., Reni M., Cascinu S., Falconi M. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Eur J Surg Oncol. 2016; 42(10): 1533–9. doi: 10.1016/j.ejso.2016.06.398.Crippa S., Bittoni A., Sebastiani E., Partelli S., Zanon S., Lanese A., Andrikou K., Muffatti F., Balzano G., Reni M., Cascinu S., Falconi M. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Eur J Surg Oncol. 2016; 42(10): 1533–9. doi: 10.1016/j.ejso.2016.06.398.Tachezy M., Gebauer F., Janot M., Uhl W., Zerbi A., Montorsi M., Perinel J., Adham M., Dervenis C., Agalianos C., Malleo G., Maggino L., Stein A., Izbicki J.R., Bockhorn M. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery. 2016; 160(1): 136–44. doi: 10.1016/j.surg.2016.02.019.Tachezy M., Gebauer F., Janot M., Uhl W., Zerbi A., Montorsi M., Perinel J., Adham M., Dervenis C., Agalianos C., Malleo G., Maggino L., Stein A., Izbicki J.R., Bockhorn M. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery. 2016; 160(1): 136–44. doi: 10.1016/j.surg.2016.02.019.Frigerio I., Regi P., Giardino A., Scopelliti F., Girelli R., Bassi C., Gobbo S., Martini P.T., Capelli P., D’Onofrio M., Malleo G., Maggino L., Viviani E., Butturini G. Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery? Ann Surg Oncol. 2017; 24(8): 2397–403. doi: 10.1245/s10434-017-5885-4.Frigerio I., Regi P., Giardino A., Scopelliti F., Girelli R., Bassi C., Gobbo S., Martini P.T., Capelli P., D’Onofrio M., Malleo G., Maggino L., Viviani E., Butturini G. Downstaging in Stage IV Pancreatic Cancer: A New Population Eligible for Surgery? Ann Surg Oncol. 2017; 24(8): 2397–403. doi: 10.1245/s10434-017-5885-4.Hellman S., Weichselbaum R.R. Oligometastases. J Clin Oncol. 1995; 13(1): 8–10. doi: 10.1200/JCO.1995.13.1.8.Hellman S., Weichselbaum R.R. Oligometastases. J Clin Oncol. 1995; 13(1): 8–10. doi: 10.1200/JCO.1995.13.1.8.Hackert T., Niesen W., Hinz U., Tjaden C., Strobel O., Ulrich A., Michalski C.W., Büchler M.W. Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol. 2017; 43(2): 358–63. doi: 10.1016/j.ejso.2016.10.023.Hackert T., Niesen W., Hinz U., Tjaden C., Strobel O., Ulrich A., Michalski C.W., Büchler M.W. Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol. 2017; 43(2): 358–63. doi: 10.1016/j.ejso.2016.10.023.Wright G.P., Poruk K.E., Zenati M.S., Steve J., Bahary N., Hogg M.E., Zuriekat A.H., Wolfgang C.L., Zeh H.J. 3rd, Weiss M.J. Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-institutional Analysis. J Gastrointest Surg. 2016; 20(11): 1830–5. doi: 10.1007/s11605-016-3256-2.Wright G.P., Poruk K.E., Zenati M.S., Steve J., Bahary N., Hogg M.E., Zuriekat A.H., Wolfgang C.L., Zeh H.J. 3rd, Weiss M.J. Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-institutional Analysis. J Gastrointest Surg. 2016; 20(11): 1830–5. doi: 10.1007/s11605-016-3256-2.Klein F., Puhl G., Guckelberger O., Pelzer U., Pullankavumkal J.R., Guel S., Neuhaus P., Bahra M. The impact of simultaneous liver resection for occult liver metastases of pancreatic adenocarcinoma. Gastroenterol Res Pract. 2012. doi: 10.1155/2012/939350.Klein F., Puhl G., Guckelberger O., Pelzer U., Pullankavumkal J.R., Guel S., Neuhaus P., Bahra M. The impact of simultaneous liver resection for occult liver metastases of pancreatic adenocarcinoma. Gastroenterol Res Pract. 2012. doi: 10.1155/2012/939350.Shi H., Li J., Fu D. Process of hepatic metastasis from pancreatic cancer: biology with clinical signifcance. J Cancer Res Clin Oncol. 2016; 142(6): 1137–61. doi: 10.1007/s00432-015-2024-0.Shi H., Li J., Fu D. Process of hepatic metastasis from pancreatic cancer: biology with clinical signifcance. J Cancer Res Clin Oncol. 2016; 142(6): 1137–61. doi: 10.1007/s00432-015-2024-0.Kajioka H., Kagawa S., Ito A., Yoshimoto M., Sakamoto S., Kikuchi S., Kuroda S., Yoshida R., Umeda Y., Noma K., Tazawa H., Fujiwara T. Targeting neutrophil extracellular traps with thrombomodulin prevents pancreatic cancer metastasis. Cancer Lett. 2021; 497: 1–13. doi: 10.1016/j.canlet.2020.10.015.Kajioka H., Kagawa S., Ito A., Yoshimoto M., Sakamoto S., Kikuchi S., Kuroda S., Yoshida R., Umeda Y., Noma K., Tazawa H., Fujiwara T. Targeting neutrophil extracellular traps with thrombomodulin prevents pancreatic cancer metastasis. Cancer Lett. 2021; 497: 1–13. doi: 10.1016/j.canlet.2020.10.015.Liang C., Qi Z., Ge H., Liang C., Zhang Y., Wang Z., Li R., Guo J. Long non-coding RNA PCAT-1 in human cancers: A meta-analysis. Clin Chim Acta. 2018; 480: 47–55. doi: 10.1016/j.cca.2018.01.043.Liang C., Qi Z., Ge H., Liang C., Zhang Y., Wang Z., Li R., Guo J. Long non-coding RNA PCAT-1 in human cancers: A meta-analysis. Clin Chim Acta. 2018; 480: 47–55. doi: 10.1016/j.cca.2018.01.043.Buscail L., Bournet B., Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2020; 17(3): 153–68. doi: 10.1038/s41575-019-0245-4.Buscail L., Bournet B., Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2020; 17(3): 153–68. doi: 10.1038/s41575-019-0245-4.Huo Y., Zhou Y., Zheng J., Jin G., Tao L., Yao H., Zhang J., Sun Y., Liu Y., Hu L.P. GJB3 promotes pancreatic cancer liver metastasis by enhancing the polarization and survival of neutrophil. Front Immunol. 2022; 13. doi: 10.3389/fmmu.2022.983116.Huo Y., Zhou Y., Zheng J., Jin G., Tao L., Yao H., Zhang J., Sun Y., Liu Y., Hu L.P. GJB3 promotes pancreatic cancer liver metastasis by enhancing the polarization and survival of neutrophil. Front Immunol. 2022; 13. doi: 10.3389/fmmu.2022.983116.Hermann C.D., Schoeps B., Eckfeld C., Munkhbaatar E., Kniep L., Prokopchuk O., Wirges N., Steiger K., Häußler D., Knolle P., Poulton E., Khokha R., Grünwald B.T., Demir I.E., Krüger A. TIMP1 expression underlies sex disparity in liver metastasis and survival in pancreatic cancer. J Exp Med. 2021; 218(11). doi: 10.1084/jem.20210911.Hermann C.D., Schoeps B., Eckfeld C., Munkhbaatar E., Kniep L., Prokopchuk O., Wirges N., Steiger K., Häußler D., Knolle P., Poulton E., Khokha R., Grünwald B.T., Demir I.E., Krüger A. TIMP1 expression underlies sex disparity in liver metastasis and survival in pancreatic cancer. J Exp Med. 2021; 218(11). doi: 10.1084/jem.20210911.Moro L., Pagano M. Epigenetic suppression of FBXL7 promotes metastasis. Mol Cell Oncol. 2020; 7(6). doi: 10.1080/23723556.2020.1833698.Moro L., Pagano M. Epigenetic suppression of FBXL7 promotes metastasis. Mol Cell Oncol. 2020; 7(6). doi: 10.1080/23723556.2020.1833698.Goulart M.R., Watt J., Siddiqui I., Lawlor R.T., Imrali A., Hughes C., Saad A., ChinAleong J., Hurt C., Cox C., Salvia R., Mantovani A., Crnogorac-Jurcevic T., Mukherjee S., Scarpa A., Allavena P., Kocher H.M. Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma. NPJ Precis Oncol. 2021; 5(1): 61. doi: 10.1038/s41698-021-00192-1.Goulart M.R., Watt J., Siddiqui I., Lawlor R.T., Imrali A., Hughes C., Saad A., ChinAleong J., Hurt C., Cox C., Salvia R., Mantovani A., Crnogorac-Jurcevic T., Mukherjee S., Scarpa A., Allavena P., Kocher H.M. Pentraxin 3 is a stromally-derived biomarker for detection of pancreatic ductal adenocarcinoma. NPJ Precis Oncol. 2021; 5(1): 61. doi: 10.1038/s41698-021-00192-1.Rhim A.D., Mirek E.T., Aiello N.M., Maitra A., Bailey J.M., McAllister F., Reichert M., Beatty G.L., Rustgi A.K., Vonderheide R.H., Leach S.D., Stanger B.Z. EMT and dissemination precede pancreatic tumor formation. Cell. 2012; 148(1–2): 349–61. doi: 10.1016/j.cell.2011.11.025.Rhim A.D., Mirek E.T., Aiello N.M., Maitra A., Bailey J.M., McAllister F., Reichert M., Beatty G.L., Rustgi A.K., Vonderheide R.H., Leach S.D., Stanger B.Z. EMT and dissemination precede pancreatic tumor formation. Cell. 2012; 148(1–2): 349–61. doi: 10.1016/j.cell.2011.11.025.Tuveson D.A., Neoptolemos J.P. Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell. 2012; 148(1–2): 21–3. doi: 10.1016/j.cell.2011.12.021.Tuveson D.A., Neoptolemos J.P. Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell. 2012; 148(1–2): 21–3. doi: 10.1016/j.cell.2011.12.021.Haeno H., Gonen M., Davis M.B., Herman J.M., IacobuzioDonahue C.A., Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012; 148(1–2): 362–75. doi: 10.1016/j.cell.2011.11.060.Haeno H., Gonen M., Davis M.B., Herman J.M., IacobuzioDonahue C.A., Michor F. Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies. Cell. 2012; 148(1–2): 362–75. doi: 10.1016/j.cell.2011.11.060.Addeo P., Oussoultzoglou E., Fuchshuber P., Rosso E., Nobili C., Langella S., Jaeck D., Bachellier P. Safety and outcome of combined liver and pancreatic resections. Br J Surg. 2014; 101(6): 693–700. doi: 10.1002/bjs.9443.Addeo P., Oussoultzoglou E., Fuchshuber P., Rosso E., Nobili C., Langella S., Jaeck D., Bachellier P. Safety and outcome of combined liver and pancreatic resections. Br J Surg. 2014; 101(6): 693–700. doi: 10.1002/bjs.9443.Kim Y., Kim S.C., Song K.B., Kim J., Kang D.R., Lee J.H., Park K.M., Lee Y.J. Improved survival after palliative resection of unsuspected stage IV pancreatic ductal adenocarcinoma. HPB (Oxford). 2016; 18(4): 325–31. doi: 10.1016/j.hpb.2015.10.014.Kim Y., Kim S.C., Song K.B., Kim J., Kang D.R., Lee J.H., Park K.M., Lee Y.J. Improved survival after palliative resection of unsuspected stage IV pancreatic ductal adenocarcinoma. HPB (Oxford). 2016; 18(4): 325–31. doi: 10.1016/j.hpb.2015.10.014.Gebauer F., Damanakis A.I., Popp F., Quaas A., Kütting F., Lutz K., Held S., Deuß B., Göser T., Waldschmidt D., Bruns C. Study protocol of an open-label, single arm phase II trial investigating the efcacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fuorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC). BMC Cancer. 2021; 21(1): 1239. doi: 10.1186/s12885-021-08966-3.Gebauer F., Damanakis A.I., Popp F., Quaas A., Kütting F., Lutz K., Held S., Deuß B., Göser T., Waldschmidt D., Bruns C. Study protocol of an open-label, single arm phase II trial investigating the efcacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fuorouracil/Folinic acid followed by curative surgical resection in patients with hepatic Oligometastatic adenocarcinoma of the pancreas (HOLIPANC). BMC Cancer. 2021; 21(1): 1239. doi: 10.1186/s12885-021-08966-3.Yamanaka M., Hayashi M., Yamada S., Sonohara F., Takami H., Inokawa Y., Shimizu D., Hattori N., Kanda M., Tanaka C., Nakayama G., Koike M., Kodera Y. A Possible Defnition of Oligometastasis in Pancreatic Cancer and Associated Survival Outcomes. Anticancer Res. 2021; 41(8): 3933–40. doi: 10.21873/anticanres.15189.Yamanaka M., Hayashi M., Yamada S., Sonohara F., Takami H., Inokawa Y., Shimizu D., Hattori N., Kanda M., Tanaka C., Nakayama G., Koike M., Kodera Y. A Possible Defnition of Oligometastasis in Pancreatic Cancer and Associated Survival Outcomes. Anticancer Res. 2021; 41(8): 3933–40. doi: 10.21873/anticanres.15189.Satoi S., Yamamoto T., Hashimoto D., Yamaki S., Matsui Y., Ikeura T., Boku S., Shibata N., Tsybulskyi D., Sekimoto M. Oncological role of surgical resection in patients with pancreatic ductal adenocarcinoma with liver-only synchronous metastases in a single-center retrospective study. J Gastrointest Oncol. 2023; 14(6): 2587–99. doi: 10.21037/jgo-23-655.Satoi S., Yamamoto T., Hashimoto D., Yamaki S., Matsui Y., Ikeura T., Boku S., Shibata N., Tsybulskyi D., Sekimoto M. Oncological role of surgical resection in patients with pancreatic ductal adenocarcinoma with liver-only synchronous metastases in a single-center retrospective study. J Gastrointest Oncol. 2023; 14(6): 2587–99. doi: 10.21037/jgo-23-655.Ushida Y., Inoue Y., Oba A., Mie T., Ito H., Ono Y., Sato T., Ozaka M., Sasaki T., Saiura A., Sasahira N., Takahashi Y. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modifed FOLFIRINOX or Gemcitabine Plus Nabpaclitaxel: A Single-Center Retrospective Study. Ann Surg Oncol. 2022; 29(8): 5038–50. doi: 10.1245/s10434-022-11503-6.Ushida Y., Inoue Y., Oba A., Mie T., Ito H., Ono Y., Sato T., Ozaka M., Sasaki T., Saiura A., Sasahira N., Takahashi Y. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modifed FOLFIRINOX or Gemcitabine Plus Nabpaclitaxel: A Single-Center Retrospective Study. Ann Surg Oncol. 2022; 29(8): 5038–50. doi: 10.1245/s10434-022-11503-6.Hamad A., Underhill J., Ansari A., Thayaparan V., Cloyd J.M., Li Y., Pawlik T.M., Tsung A., Abushahin L., Ejaz A. Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: An analysis of the National Cancer Database. Surgery. 2022; 171(6): 1464–70. doi: 10.1016/j.surg.2021.12.029.Hamad A., Underhill J., Ansari A., Thayaparan V., Cloyd J.M., Li Y., Pawlik T.M., Tsung A., Abushahin L., Ejaz A. Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: An analysis of the National Cancer Database. Surgery. 2022; 171(6): 1464–70. doi: 10.1016/j.surg.2021.12.029.Tanaka M., Heckler M., Mihaljevic A.L., Sun H., Klaiber U., Heger U., Büchler M.W., Hackert T. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX. Eur J Surg Oncol. 2019; 45(8): 1453–9. doi: 10.1016/j.ejso.2019.03.039.Tanaka M., Heckler M., Mihaljevic A.L., Sun H., Klaiber U., Heger U., Büchler M.W., Hackert T. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX. Eur J Surg Oncol. 2019; 45(8): 1453–9. doi: 10.1016/j.ejso.2019.03.039.De Simoni O., Scarpa M., Tonello M., Pilati P., Tolin F., Spolverato Y., Gruppo M. Oligometastatic Pancreatic Cancer to the Liver in the Era of Neoadjuvant Chemotherapy: Which Role for Conversion Surgery? A Systematic Review and MetaAnalysis. Cancers (Basel). 2020; 12(11): 3402. doi: 10.3390/cancers12113402.De Simoni O., Scarpa M., Tonello M., Pilati P., Tolin F., Spolverato Y., Gruppo M. Oligometastatic Pancreatic Cancer to the Liver in the Era of Neoadjuvant Chemotherapy: Which Role for Conversion Surgery? A Systematic Review and MetaAnalysis. Cancers (Basel). 2020; 12(11): 3402. doi: 10.3390/cancers12113402.Schwarz C., Fitschek F., Primavesi F., Stättner S., Margonis G.A., Weiss M.A., Stavrou G.A., Oldhafer K.J., Kornprat P., Wundsam H., Fischer I., Längle F., Függer R., Hauer A., Klug R., Kieler M., Prager G., Schindl M., Stremitzer S., Bodingbauer M., Sahora K., Kaczirek K. Metachronous hepatic resection for liver only pancreatic metastases. Surg Oncol. 2020; 35: 169–73. doi: 10.1016/j.suronc.2020.08.005.Schwarz C., Fitschek F., Primavesi F., Stättner S., Margonis G.A., Weiss M.A., Stavrou G.A., Oldhafer K.J., Kornprat P., Wundsam H., Fischer I., Längle F., Függer R., Hauer A., Klug R., Kieler M., Prager G., Schindl M., Stremitzer S., Bodingbauer M., Sahora K., Kaczirek K. Metachronous hepatic resection for liver only pancreatic metastases. Surg Oncol. 2020; 35: 169–73. doi: 10.1016/j.suronc.2020.08.005.Zhou W., Wang D., Lou W. Current Role of Surgery in Pancreatic Cancer With Synchronous Liver Metastasis. Cancer Control. 2020; 27(1): 1–7. doi: 10.1177/1073274820976593.Zhou W., Wang D., Lou W. Current Role of Surgery in Pancreatic Cancer With Synchronous Liver Metastasis. Cancer Control. 2020; 27(1): 1–7. doi: 10.1177/1073274820976593.Mitsuka Y., Yamazaki S., Yoshida N., Yan M., Higaki T., Takayama T. Time interval-based indication for liver resection of metastasis from pancreatic cancer. World J Surg Oncol. 2020; 18(1): 294. doi: 10.1186/s12957-020-02058-5.Mitsuka Y., Yamazaki S., Yoshida N., Yan M., Higaki T., Takayama T. Time interval-based indication for liver resection of metastasis from pancreatic cancer. World J Surg Oncol. 2020; 18(1): 294. doi: 10.1186/s12957-020-02058-5.

The authors declare that there are no conflicts of interest present.